



Financial Results for the Fiscal Year Ended March 31, 2015

May 08, 2015
Exchange where listed: TSE

Name of listed company : **TERUMO CORPORATION**
(URL <http://www.terumo.com/>)
Company code number : 4543
Representative: Yutaro Shintaku, President and Representative Director
Please address all communications to : Atsuo Omagari, General Manager, Corporate Communication Dept.
Phone : +81 / 3-6742-8550

1. Consolidated Financial Highlights for the Year Ended March 2015 (From April 1, 2014 to March 31, 2015)

(1) Consolidated operating results

(Notes: The amounts shown below ignore values of less than a million yen)

	Net sales		Operating income		Ordinary income		Net income	
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%
Year ended March, 2015	489,506	4.7	67,456	3.3	70,730	10.9	38,470	12.8
Year ended March, 2014	467,359	16.2	65,288	22.7	63,802	24.2	34,096	(27.5)

(Notes) Comprehensive income: March 2015: 88,986 million yen (25.0%) March 2014: 71,166 million yen (-24.1%)

	Net income per share	Net income per share, fully diluted	Net income per stockholders' equity	Ordinary income per total assets	Operating income per Net sales
	(Yen)	(Yen)	%	%	%
Year ended March, 2015	101.33	99.12	7.2	7.8	13.8
Year ended March, 2014	89.78	89.78	7.3	8.0	14.0

(Notes) Equity in earnings of affiliates: March 2015: -65 million yen March 2014: 132 million yen

Terumo Corporation executed a two-for-one stock split on its common shares effective April 1, 2014.

Net income per share and Net income per share, fully diluted have been adjusted retrospectively to reflect the effect of the stock split.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	(Millions of yen)	(Millions of yen)	%	(Yen)
As of March 31, 2015	992,073	573,523	57.8	1,513.73
As of March 31, 2014	832,814	496,245	59.6	1,306.72

(Notes) Shareholders' equity: March 31, 2015: 573,444 million yen March 31, 2014: 496,225 million yen

Terumo Corporation executed a two-for-one stock split on its common shares effective April 1, 2014.

Net asset per share has been adjusted retrospectively to reflect the effect of the stock split.

(3) Consolidated statements of cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents, end of period
	(Millions of yen)	(Millions of yen)	(Millions of yen)	(Millions of yen)
Year ended March, 2015	73,110	(40,421)	44,121	176,662
Year ended March, 2014	96,259	(52,744)	(31,785)	92,498

2. Dividends

	Cash dividends per share				
	1st quarter	2nd quarter	3rd quarter	4th quarter	total
	(Yen)	(Yen)	(Yen)	(Yen)	(Yen)
Year ended March, 2014	—	29.00	—	29.00	58.00
Year ended March, 2015	—	14.50	—	16.00	30.50
Year ending March, 2016 (forecast)	—	16.00	—	16.00	32.00

(Notes) Terumo Corporation executed a two-for-one stock split on its common shares effective April 1, 2014.

Cash dividends per share for the year ending March, 2015 and the year ending March, 2016 (forecast) have reflected this stock split.

3. Consolidated Forecast for the Year Ending March 2016 (From April 1, 2015 to March 31, 2016)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Yen)
Half year ending September, 2015	250,000	7.2	31,000	(6.0)	29,500	(13.3)	17,500	(20.0)	46.09
Year ending March, 2016	520,000	6.2	70,000	3.8	67,000	(5.3)	39,500	2.7	104.04

(Notes) Assumed exchange rate for fiscal year ending March, 2016: USD1=JPY120, EUR1=JPY130

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

4. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2014		As of March 31, 2015	
	Amount	%	Amount	%
(Assets)				
I Current assets	310,985	37.3	412,458	41.6
Cash and deposits	95,618		129,679	
Notes and accounts receivable-trade	101,520		104,944	
Securities	—		50,000	
Marchandise and finished goods	60,034		65,295	
Work in process	10,262		10,228	
Raw materials and supplies	23,668		25,948	
Deferred tax assets	12,340		13,949	
Other	8,933		13,871	
Allowance for doubtful accounts	(1,394)		(1,458)	
II Noncurrent assets	520,332	62.5	575,842	58.0
1. Property, plant and equipment	157,755	18.9	178,496	18.0
Buildings and structures	54,215		60,783	
Machinery, equipment and vehicles	43,916		45,616	
Land	21,757		22,023	
Lease assets	406		895	
Construction in progress	27,974		39,029	
Other	9,483		10,147	
2. Intangible assets	304,756	36.7	331,990	33.4
Goodwill	154,161		166,990	
Customer relationships	93,968		103,217	
Other	56,626		61,781	
3. Investments and other assets	57,820	6.9	65,355	6.6
Investment securities	37,954		45,461	
Deferred tax assets	5,323		259	
Retirement benefit asset	2,573		6,786	
Other	11,969		12,847	
III Deferred assets	1,496	0.2	3,772	0.4
Total assets	832,814	100.0	992,073	100.0

(Millions of yen)

	As of March 31, 2014		As of March 31, 2015	
	Amount	%	Amount	%
(Liabilities)		%		%
I Current liabilities	160,936	19.3	129,947	13.1
Notes and accounts payable-trade	38,147		38,484	
Short-term debt	260		364	
Current portion of long-term debt	4,652		5,417	
Lease obligations	225		208	
Current portion of bonds payable	40,000		—	
Income taxes payable	18,401		19,714	
Deferred tax liabilities	94		105	
Provision for bonuses	4,849		5,560	
Provision for directors' bonuses	109		142	
Notes and accounts payable-facilities	8,425		8,667	
Other	45,769		51,282	
II Noncurrent liabilities	175,632	21.1	288,602	29.1
Bonds payable	40,000		40,000	
Convertible bond-type bonds with subscription rights to shares	—		100,233	
Long-term debt	76,769		79,141	
Lease obligations	299		278	
Deferred tax liabilities	47,795		50,013	
Provision for directors' retirement benefits	66		66	
Retirement benefit liability	3,124		7,020	
Asset retirement obligations	220		233	
Other	7,354		11,615	
Total liabilities	336,568	40.4	418,550	42.2
I Shareholders' equity	444,396	53.4	471,102	47.5
Capital stock	38,716		38,716	
Capital surplus	52,103		52,103	
Retained earnings	353,600		383,317	
Treasury stock	(24)		(3,035)	
II Accumulated other comprehensive income	51,828	6.2	102,341	10.3
Valuation difference on available-for-sale securities	11,269		16,910	
Deferred gains or losses on hedges	(2)		—	
Foreign currency translation adjustments	43,377		89,043	
Accumulated adjustments for retirement benefit	(2,816)		(3,611)	
III Stock subscription rights	20	0.0	78	0.0
Total net assets	496,245	59.6	573,523	57.8
Total liabilities, net assets	832,814	100.0	992,073	100.0

(2) Consolidated Statements of Income

(Millions of yen)

	For the year ended			For the year ended		
	March 31, 2014			March 31, 2015		
	Amount			Amount		
			%			%
I Net sales		467,359	100.0		489,506	100.0
II Cost of sales		225,348	48.2		233,480	47.7
Gross profit		242,011	51.8		256,025	52.3
III Selling, general and administrative expenses		176,722	37.8		188,569	38.5
Operating income		65,288	14.0		67,456	13.8
IV Non-operating income						
Interest income		459			566	
Dividends income		338			365	
Royalty income		116			200	
Foreign exchange gains		3,250			6,598	
Equity in earnings of affiliates		132			—	
Other		1,203	5,501	1.2	1,098	8,829
						1.8
V Non-operating expenses						
Interest expenses		1,542			1,254	
Sales discounts		661			417	
Equity in losses of affiliates		—			65	
Loss on disposal of inventories		836			267	
Structural reform-related expenses		—			797	
Other		3,947	6,988	1.5	2,752	5,555
						1.1
Ordinary income		63,802	13.7		70,730	14.5
VI Extraordinary gains						
Gain on sales of noncurrent assets		743			692	
Gain on sales of investment securities		—			559	
Gain on transfer of businesses		666			—	
Gain on adjustment of account payable		—			2,030	
Settlement received		6,000	7,410	1.5	—	3,282
						0.7
VII Extraordinary losses						
Loss on disposal of noncurrent assets		995			1,160	
Impairment loss		15,351			1,625	
Loss on liquidation of subsidiaries and affiliates		—			597	
Restructuring loss		—			5,607	
Directors' retirement benefits		33			—	
Loss on liquidation of businesses		740			974	
Loss on information system failure		1,185	18,305	3.9	—	9,965
						2.1
Income before income taxes and minority interests		52,907	11.3		64,046	13.1
Income taxes-current		26,637			29,954	
Income taxes-deferred		(7,856)	18,780	4.0	(4,378)	25,575
						5.2
Income before minority interests		34,126	7.3		38,470	7.9
Minority interests in income		30	0.0		—	—
Net income		34,096	7.3		38,470	7.9

(3) Consolidated Statements of Comprehensive Income

(Millions of yen)

	For the year ended March 31, 2014		For the year ended March 31, 2015	
	Amount		Amount	
I Income before minority interests	34,126		38,470	
II Other comprehensive income				
Valuation difference on available-for-sale securities	3,811		5,640	
Deferred gains or losses on hedges	(2)		2	
Foreign currency translation adjustments	33,234		45,665	
Remeasurements of defined benefit plans	—		(795)	
Share of other comprehensive income of associates accounted for using equity method	(3)	37,039	1	50,515
Comprehensive income		71,166		88,986
Attributable to:				
Shareholders of Terumo Corporation		71,179		88,986
Minority interests		(13)		—

(4) Statement of changes in net assets

(Millions of yen)

Year ended March 2014	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Shareholders' equity total
Beginning of period	38,716	52,103	329,188	(9)	419,999
Cumulative effect of changes in accounting policies					—
Beginning of period as restated	38,716	52,103	329,188	(9)	419,999
Changes during this fiscal year					
Dividends from surplus			(9,683)		(9,683)
Net income			34,096		34,096
Purchase of treasury stock				(14)	(14)
Changes of items other than shareholders' equity (net)					
Total changes during this fiscal year	—	—	24,412	(14)	24,397
Ending of period	38,716	52,103	353,600	(24)	444,396

Year ended March 2014	Accumulated other comprehensive income					Subscription rights to shares	Minority interests	Net assets total
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustments	Remeasurements of defined benefit plans	Accumulated other comprehensive income total			
Beginning of period	7,458	—	10,099	—	17,557	—	352	437,909
Cumulative effect of changes in accounting policies								—
Beginning of period as restated	7,458	—	10,099	—	17,557	—	352	437,909
Changes during this fiscal year								
Dividends from surplus								(9,683)
Net income								34,096
Purchase of treasury stock								(14)
Changes of items other than shareholders' equity (net)	3,811	(2)	33,278	(2,816)	34,270	20	(352)	33,938
Total changes during this fiscal year	3,811	(2)	33,278	(2,816)	34,270	20	(352)	58,335
Ending of period	11,269	(2)	43,377	(2,816)	51,828	20	—	496,245

(Millions of yen)

Year ended March 2015	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Shareholders' equity total
Beginning of period	38,716	52,103	353,600	(24)	444,396
Cumulative effect of changes in accounting policies			2,258		2,258
Beginning of period as restated	38,716	52,103	355,859	(24)	446,655
Changes during this fiscal year					
Dividends from surplus			(11,012)		(11,012)
Net income			38,470		38,470
Purchase of treasury stock				(3,010)	(3,010)
Changes of items other than shareholders' equity (net)					
Total changes during this fiscal year	—	—	27,458	(3,010)	24,447
Ending of period	38,716	52,103	383,317	(3,035)	471,102

Year ended March 2015	Accumulated other comprehensive income					Subscription rights to shares	Net assets total
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustments	Remeasurements of defined benefit plans	Accumulated other comprehensive income total		
Beginning of period	11,269	(2)	43,377	(2,816)	51,828	20	496,245
Cumulative effect of changes in accounting policies							2,258
Beginning of period as restated	11,269	(2)	43,377	(2,816)	51,828	20	498,504
Changes during this fiscal year							
Dividends from surplus							(11,012)
Net income							38,470
Purchase of treasury stock							(3,010)
Changes of items other than shareholders' equity (net)	5,640	2	45,665	(795)	50,513	58	50,571
Total changes during this fiscal year	5,640	2	45,665	(795)	50,513	58	75,019
Ending of period	16,910	—	89,043	(3,611)	102,341	78	573,523

(5) Consolidated statements of cash flows

(Millions of yen)

	For the year ended	For the year ended
	March 31, 2014	March 31, 2015
	Amount	Amount
I Net cash provided by (used in) operating activities		
Income before income taxes	52,907	64,046
Depreciation and amortization	30,322	30,363
Impairment loss	15,351	1,625
Amortization of goodwill	9,559	10,329
Equity in (earnings) losses of affiliates	(132)	65
Increase(decrease) in provision for retirement benefits	(1,247)	—
Decrease (increase) in net defined benefit asset	(1,899)	1,135
Increase(decrease) in net defined benefit liability	1,506	(215)
Increase(decrease) in provision for directors' retirement benefits	(132)	—
Increase(decrease) in allowance for doubtful accounts	73	14
Increase(decrease) in provision for directors' bonuses	0	32
Interest and dividends income	(798)	(932)
Interest expenses	1,542	1,254
Foreign exchange losses (gains)	(3,210)	(4,483)
Structural reform-related expenses	—	797
Gain on transfer of business	(666)	—
Gain on adjustment of account payable	—	(2,030)
Settlement received	(6,000)	—
Loss (gain) on sales of noncurrent assets	(743)	(692)
Loss (gain) on disposal of noncurrent assets	995	1,160
Loss (gain) on sales of investment securities	—	(559)
Loss on liquidation of subsidiaries and affiliates	—	597
Restructuring loss	—	5,607
Directors' retirement benefits	33	—
Loss on liquidation of businesses	740	974
Loss on system fault	1,185	—
Payments cash contribution of securities to retirement benefit trust	(3,600)	—
Decrease (increase) in notes and accounts receivable-trade	(506)	1,317
Decrease (increase) in inventories	(3,618)	(1,241)
Increase (decrease) in trade payable	(1,096)	(801)
Other, net	4,849	(2,242)
Subtotal	95,411	106,121
Interest and dividends income received	1,020	1,165
Interest expenses paid	(1,522)	(1,282)
Income taxes paid	(2,875)	(31,001)
Payments for structural reform-related expenses	—	(382)
Settlement package received	6,000	—
Payments for loss on liquidation of subsidiaries	—	(565)
Payments for restructuring loss	—	(515)
Payments for directors' retirement benefits	(33)	—
Payments for loss on liquidation of business	—	(179)
Payments for information system failure	(943)	(250)
Payments for environmental expenses	(798)	—
Net cash provided by (used in) operating activities	96,259	73,110
II Net cash provided by (used in) investment activities		
Payments into time deposits	(767)	(1,201)
Proceeds from withdrawal of time deposits	1,182	1,505
Purchase of property, plant and equipment	(39,933)	(37,342)
Proceeds from sales of property, plant and equipment	953	1,168
Purchase of intangible assets	(4,960)	(3,683)
Payments for performance to asset retirement obligations	(420)	—
Purchase of investment securities	(1,823)	(429)
Proceeds from sales of investment securities	—	1,434
Collection of lease deposits	—	459
Payments for acquisition of business	(1,828)	(54)
Purchase of investments in subsidiaries resulting in change in scope of consolidation	(374)	—
Purchase of stocks of subsidiaries	(1,519)	—
Proceeds from transfer of businesses	1,815	—
Other, net	(5,069)	(2,276)
Net cash provided by (used in) investment activities	(52,744)	(40,421)
III Net cash provided by (used in) financing activities		
Increase in short-term debt	253	257
Decrease in short-term debt	(49)	(202)
Net increase (decrease) in short-term debt	(18,000)	—
Proceeds from long-term debt	—	3,018
Repayments of long-term debt	(4,006)	(4,963)
Proceeds from issuance of bonds with subscription rights to shares	—	100,250
Redemption of bonds	—	(40,000)
Repayments of financial lease obligations	(284)	(214)
Purchase of treasury stock	(14)	(3,010)
Cash dividends paid	(9,683)	(11,012)
Net cash provided by (used in) financing activities	(31,786)	44,121
IV Effect of exchange rate changes on cash and cash equivalents	5,603	7,353
V Net increase(decrease) in cash and cash equivalents	17,332	84,164
VI Cash and cash equivalents at beginning of period	75,165	92,498
VII Cash and cash equivalents at end of period	92,498	176,662

(6)Notes

<Significant accounting policies in preparing the consolidated financial statements>

Changes in accounting policy

(Adoption of Accounting Standard for Retirement Benefits)

Effective from the beginning of the fiscal year ending March 31, 2015, the Company and its consolidated domestic subsidiaries have applied the Accounting Standard for Retirement Benefits (ASBJ Statement No. 26, May 17, 2012 (hereinafter, the "Statement No. 26") and Guidance on Accounting Standard for Retirement Benefits (ASBJ Guidance No. 25, March 26, 2017 (hereinafter, the "Guidance No. 25")), and the method of calculating retirement benefit obligations and service costs are revised, with the method of attributing benefits to accounting periods changed from the straight-line basis to the benefit formula basis, and the method of determination of the discount rate changed to several weighted average discount rates which are set at the time of each expected retirement benefit payment.

In accordance with the article 37 of the Statement No. 26, the effect of the change in calculation methods of retirement benefit obligations and service costs arising from initial application has been recognized in "Retained earnings" at the beginning of the fiscal year ending March 31, 2015.

As a result, "Retirement benefit assets" and "Retained earnings" have increased by ¥3,509 million and ¥2,258 million, respectively, at the beginning of the fiscal year ending March 31, 2015. "Operating income", "Ordinary income" and "Income before income taxes and minority interests" have increased by ¥632 million, respectively, for the current year. And net assets per share, net income per share and net income per share, fully diluted have increased by ¥5.96, ¥1.67 and ¥1.63, respectively.

5. Segment Information

[Reportable Segments]

(1) Fiscal Year Ended March 31, 2014

(Millions of yen)

	Reportable Segments				Adjustment	Total
	Cardiac & Vascular Company	General Hospital Company	Blood Management Company	Subtotal		
Sales and operating income:						
Sales to customer	208,430	164,089	94,871	467,391	(32)	467,359
Internal sales	—	—	—	—	—	—
Sales total	208,430	164,089	94,871	467,391	(32)	467,359
Segment income (Excl. Amortization)	43,970	20,797	18,571	83,339	(1,740)	81,599
Segment income (loss)	42,095	20,797	4,135	67,028	(1,740)	65,288
Segment income%(Excl. Amortization)	21.1	12.7	19.6	17.8	—	17.5
Segment assets	226,599	171,316	337,934	735,850	96,963	832,814
Others:						
Depreciation and amortization	8,554	8,660	12,245	29,460	861	30,322
Amortization of goodwill	1,874	—	7,684	9,559	—	9,559
Net increase of tangible and intangible noncurrent assets	22,000	13,037	10,583	45,621	1,002	46,624

- Notes: 1. The (1,740) million yen adjustment to segment income is the sum of (129) million yen for inventories and (1,610) million yen for others.
2. Adjustment to segment assets, which amounted to 96,963 million yen, mainly includes investments in "Cash and deposit", "Investments securities", "Deferred tax assets" and assets of the Administrative Department.
3. Segment income is adjusted to be consistent with "Operating income" shown on the consolidated statements of income.

(2) Fiscal Year Ending March 31, 2015

(Millions of yen)

	Reportable Segments				Adjustment	Total
	Cardiac & Vascular Company	General Hospital Company	Blood Management Company	Subtotal		
Sales and operating income:						
Sales to customer	229,155	161,462	98,887	489,506	—	489,506
Internal sales	—	—	—	—	—	—
Sales total	229,155	161,462	98,887	489,506	—	489,506
Segment income (Excl. Amortization)	47,496	20,833	18,480	86,811	(1,676)	85,134
Segment income (loss)	45,625	20,833	2,673	69,132	(1,676)	67,456
Segment income%(Excl. Amortization)	20.7	12.9	18.7	17.7	—	17.4
Segment assets	241,401	196,842	382,438	820,683	171,389	992,073
Others:						
Depreciation and amortization	7,450	8,584	12,935	28,970	1,392	30,363
Amortization of goodwill	1,870	—	8,458	10,329	—	10,329
Net increase of tangible and intangible noncurrent assets	16,978	12,240	11,434	40,653	788	41,441

- Notes: 1. The (1,676) million yen adjustment to segment income is the sum of (1,541) million yen for inventories and (134) million yen for others.
2. Adjustment to segment assets, which amounted to 171,389 million yen, mainly includes investments in "Cash and deposit", "Investments securities", "Deferred tax assets" and assets of the Administrative Department.
3. Segment income is adjusted to be consistent with "Operating income" shown on the quarterly consolidated statements of income.

(Changes in the category of segments)

As a result of reclassification in performance management among overseas subsidiaries, "Harvest Technologies Corporation" and "Harvest Technologies GmbH" have been transferred from "Cardiac & Vascular Company" to "Blood Management Company" since October 1, 2014. This change caused an increase and decrease of 145 million yen in "Segment income" of "Cardiac & Vascular Company" and "Blood Management Company", respectively, for the previous fiscal year.

(Changes in the name of segments)

"Cardiac & Vascular Business", "General Hospital Business" and "Blood Management Business" changed their names to "Cardiac & Vascular Company", "General Hospital Company" and "Blood Management Company", respectively, from the first quarter of fiscal year ending March 31, 2015. This change is reflected retrospectively.

(Note) Main products belonging to each business segment

Business segments	Sub-segments	Main products
Cardiac & Vascular Company	Interventional Systems	Angiographic catheters, PTCA balloon catheters, Coronary stents
	Neurovascular	Neuro interventional coils, etc.
	CV Systems	Oxygenators, Cardio-pulmonary bypass system, etc.
	Vascular Graft	Artificial vascular grafts, Stent grafts
General Hospital Company	General Hospital Products	Syringes, Needles, Blood collection tubes, Solution sets, I.V.catheters, Infusion pumps, Syringe pumps, etc.
	Pharmaceutical and Nutrition	I.V.solutions, Nutritious food, CAPD systems, etc.
	D&D	Prefilled syringes, Pain management systems etc.
	DM and Consumer Healthcare	Blood glucose monitoring systems, Digital thermometers, Blood pressure monitors, etc.
Blood Management Company	—	Blood bags, Automated blood collection system, Therapeutic apheresis system, Cell expansion system, etc.

(Supplementary Information)

[Geographic Segments]

(1) Fiscal year ended March 31, 2014 (Millions of yen)

	Japan	Europe	Americas	Asia and others	Total
Sales	189,041	96,892	110,972	70,452	467,359
Tangible noncurrent assets	105,400	10,712	17,722	23,919	157,755

(2) Fiscal year ended March 31, 2015 (Millions of yen)

	Japan	Europe	Americas	Asia and others	Total
Sales	183,146	104,600	125,310	76,448	489,506
Tangible noncurrent assets	110,226	10,180	25,687	32,402	178,496

[Impairment Loss on noncurrent assets]

(1) Fiscal year ended March 31, 2014 (Millions of yen)

	Reportable Segments					
	Cardiac & Vascular Company	General Hospital Company	Blood Management Company	Subtotal	Company	Total
Impairment Loss	7,594	3,454	1,965	13,014	2,336	15,351

(2) Fiscal year ended March 31, 2015 (Millions of yen)

	Reportable Segments					
	Cardiac & Vascular Company	General Hospital Company	Blood Management Company	Subtotal	Company	Total
Impairment Loss	1,625	—	—	1,625	—	1,625

[Goodwill]

(1) Fiscal year ended March 31, 2014 (Millions of yen)

	Reportable Segments					
	Cardiac & Vascular Company	General Hospital Company	Blood Management Company	Subtotal	Company	Total
Goodwill	18,051	—	136,110	154,161	—	154,161

(2) Fiscal year ended March 31, 2015 (Millions of yen)

	Reportable Segments					
	Cardiac & Vascular Company	General Hospital Company	Blood Management Company	Subtotal	Company	Total
Goodwill	17,648	—	149,342	166,990	—	166,990